相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2019)
LBA81_PRPhase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
S M Gadgeel et al.
ANNALS OF ONCOLOGY (2019)
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
J. Zugazagoitia et al.
ANNALS OF ONCOLOGY (2019)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer
Joshua Bauml et al.
CLINICAL CANCER RESEARCH (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
Martin E. Gutierrez et al.
CLINICAL LUNG CANCER (2017)
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Petra Martin et al.
BRITISH JOURNAL OF CANCER (2016)
Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?
Charles Lim et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
C. Lim et al.
ANNALS OF ONCOLOGY (2015)